A new boronated porphyrin (STA-BX909) for neutron capture therapy: An in vitro survival assay and in vivo tissue uptake study

Cancer Letters

Volumn 141, Issue 1-2, 1999, Pages 203-209

  Matsumura, Akira ^a   Shibata, Yasushi ^a   Yamamoto, Tetsuya ^a   Yoshida, Fumiyo ^a   Isobe, Tomonori ^a   Nakai, Kei ^a   Hayakawa, Yoshinori ^b   Kiriya, Minako ^c   Shimojo, Nobuhiro ^c   Ono, Koji ^d   Sakata, Isao ^e   Nakajima, Susumu ^f   Okumura, Masafumi ^g   Nose, Tadao ^a  

^a Univ T   (Japan)

^b Proton Medical Center   (Japan)

^c Department of Environmental Medicine ^*  (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e Toyo Hakka Co Ltd   (Japan)

^f ASAHIKAWA MEDICAL COLLEGE   (Japan)

^g Nihon Schering Research Institute   (Japan)

Author keywords

9L; Boronated porphyrin; Glioma; Neutron capture therapy

Indexed keywords

BOROCAPTATE; BORON DERIVATIVE; PORPHYRIN DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG UPTAKE; GLIOMA CELL; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BOROHYDRIDES; BORON; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; CELL SURVIVAL; GLIOMA; METALLOPORPHYRINS; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; SULFHYDRYL COMPOUNDS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033018985     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00105-6     Document Type: Article

References (18)

1. Soloway A.H., Hatanaka H., Davis M.A. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydral boron compounds. J. Med. Chem. 10:1967;714-717.
2. Hatanaka H., Nakagawa Y. Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys. 28:1994;1061-1066.
3. Ueda S., Imahori Y., Ohmori Y., Yoshino E., Ono K., Kobayashi T., Takagaki M., Oda Y., Ido T., Mishima Y. Positron emission tomography and boron neutron capture therapy system to patient with malignant brain tumor. Mishima Y. The First Clinical Trial Using 10B-BPA. Cancer Neutron Capture Therapy. 1996;823 Plenum Press, New York.
4. Coderre J., Bergland R., Capala J., Hadha M., Chanana A.D., Elowitz E., Joel D.D., Liu H.B., Slatkin D.N. Boron neutron capture therapy for glioblastoma multiforme using p-boronophenyl alanine and epithermal neutrons: trial design and early clinical results. J. Neurooncol. 33:1997;141-152.
5. Fankhauser H., Stragliotto G., Zbinden P. Borocaptate sodium (BSH) pharmacokinetics in glioma patients. Gabel D., Moss R. Boron Neutron Capture Therapy. Toward Clinical Trials of Glioma Treatment. 1992;155 Plenum Press, New York.
6. Kitamura K., Nakagawa Y., Minobe T., Masuda T., Kageji T. Radiation necrosis and related factors after boron neutron capture therapy. Larrson B., Crawford J., Weinrich R. Advances in Neutron Capture Therapy. Vol. II, Chemistry and Biology. 1997;679 Elsevier, Amsterdam.
7. Doughtery T.J. Photodynamic therapy. Adv. Exp. Med. Biol. 193:1985;313-328.
8. Kahl S.B., Koo M.S. Synthesis and properties of tetrakis-carborane carboxylate esters of 2,4-bis(alpha,beta-dihyrdroxy)ethyl deutero-porphyrin IX. Allen B.J., Moore D.J., Harrington B.V. Progress in Neutron Cancer Therapy. 1992;223 Plenum Press, New York.
9. Fairchild R.G., Kahl S.B., Laster B.H., Kalef-Ezra J., Popenoe E.A. In vitro determination of uptake, petention, distribution, biological efficacy, and toxicity of boronated compounds for neutron capture therapy: a comparison of porphyrins with sulfhydryl boron hydrides. Cancer Res. 50:1990;4860-4865.
10. Hill J.S., Kahl S.B., Kaye A.H., Stylli S.S., Koo M.S., Gonzales M.F., Vardaxis N.J., Johnson C.I. Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc. Natl. Acad. Sci. USA. 89:1992;1785-1789.
11. Matsumura A., Shibata Y., Yamamoto T., Fujimori H., Nakai K., Sakata I., Miwa N., Nakajima S., Nose T. Pharmacokinetic study of boronated metalloporphyrin (STA-BX900) and BSH in the 9L rat glioma model. Larrson B., Crawford J., Weinrich R. Advances in Neutron Capture Therapy. Vol. II, Chemistry and Biology. 1997;158 Elsevier, Amsterdam.
12. Miura M., Micca P.L., Fisher C.D., Heinrichs J.C., Donaldson J.A., Finkel G.C., Slatkin D.N. Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron capture therapy: biodistribution and toxicity in tumor-bearing mice. Int. J. Cancer. 68:1996;114-119.
13. Miura M., Micca P.L., Fisher C.D., Gordon C.R., Heinrichs J.C., Slatkin D.N. Evaluation of carborane-containing porphyrins as tumour targeting agents for boron neutron capture therapy. Br. J. Rad. 71:1998;773-781.
14. Nakajima S., Shuke N., Aburano T., Ishikawa S., Sato J., Sakata I., Takemura T. Usefulness of newly developed 99mTc-labaeled STA-R12 for tumor imaging. Jpn. J. Nucl. Medicine. 31:1994;1379-1783. (in Japanese).
15. Nakajima S., Takemura T., Sakata I. Tumor-localizing activity of porphyrin and its affinity to LDL and transferrin. Cancer Lett. 92:1995;113-118.
16. Murakami M., Ushio Y., Mihara Y., Kuratsu J., Horiuchi S., Morino Y. Cholesterol uptake by human glioma cells via receptor-mediated endocytosis of low-density lipoprotein. J. Neurosurg. 73:1990;760-767.
17. Bu G., Maksymovitch E.A., Geuze H., Schwartz A.L. Subcellular localization and endocytic function of low density lipoprotein receptor-related protein in human glioblastoma cells. J. Biol. Chem. 269:1994;29874-29882.
18. Ceberg C.P., Brun A., Kahl S.B., Koo M.S., Persson B.R.R., Salford L.G. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J. Neurosurg. 83:1995;86-92.